Development of allogeneic CAR-T cell therapies using gene-edited T-cells to treat cancer, leveraging TALEN® technology for off-the-shelf immunotherapies.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: July 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Priothera
B
Development of innovative therapies for hematological malignancies, focusing on immune modulators to enhance outcomes in allogeneic hematopoietic cell transplantation and CAR T cell therapy.
Transgene
A
Development of individualized therapeutic vaccines for early-stage solid tumor patients using viral vector technology.
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Initiatives identified among leaders
Gestion flexible du temps de travail et repos validés
“L'organisation du temps de travail inclut des mesu...” - TransgeneObtention du statut d'établissement pharmaceutique
“Genethon obtient le statut d'établissement pharmac...” - GenethonCode de conduite
“Priothera développe des thérapies innovantes pour ...” - Priothera38% of similar organizations communicate on CSR issues
+119 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports